FDA Puts Perifosine On Fast Track For Treatment Of Multiple Myeloma – Perifosine (KRX-0401) has received priority for evaluation by the FDA as an anti-cancer agent in the treatment of relapsed/refractory myeloma through the Fast Track program. The Fast Track program expedites the review of new drugs that treat serious or life-threatening conditions and have the potential to address unmet medical needs. A Phase 3 clinical trial is planned for the end of the year to investigate the …

Individuals with multiple myeloma are recommended to get both the H1N1 (“swine flu”) vaccine and the seasonal flu vaccine. In particular, most myeloma patients are advised to get the shot version of the H1N1 vaccine.

About The H1N1 Flu

The H1N1 flu, also referred to as “swine flu,” has caused thousands of hospitalizations and more than 600 deaths in the United States since it was first detected in April 2009.

It is spread through person-to-person contact, often by sneezing or …